Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial

Stone J, Bao M, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Unizony S (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Arthritis and Rheumatology Wiley

Publisher: WILEY

City/Town: HOBOKEN

Conference Proceedings Title: ARTHRITIS & RHEUMATOLOGY

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

Harvard University

United States (USA) (US) University of Groningen / Rijksuniversiteit Groningen

Netherlands (NL) Arcispedale Santa Maria Nuova

Italy (IT) Hospital for Special Surgery (HSS)

United States (USA) (US) Genentech Inc.

United States (USA) (US) National Health Service (NHS)

United Kingdom (GB) University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven

Belgium (BE) Technische Universität Dresden

Germany (DE) Universitat de Barcelona (UB) / University of Barcelona

Spain (ES)

How to cite

APA:

Stone, J., Bao, M., Han, J., Aringer, M., Blockmans, D., Brouwer, E.,... Unizony, S. (2019). Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial. In ARTHRITIS & RHEUMATOLOGY. HOBOKEN: WILEY.

MLA:

Stone, John, et al. "Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial." Proceedings of the ARTHRITIS & RHEUMATOLOGY HOBOKEN: WILEY, 2019.

BibTeX: Download